Comparison of the Cost of 4 Kinds of Second-line Drug Treatment Regimes for Non-small Cell Lung Cancer
- VernacularTitle:4种非小细胞肺癌二线药物治疗方案费用比较研究
- Author:
Bao LIU
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Second-line drug treatment;
Pharmaeconomics
- From:
China Pharmacy
2007;0(26):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the cost of 4 kinds of second-line drug treatment regimes(docetaxel, pemetrexed, gefitinib,and erlotinib)for non-small-cell lung cancer(NSCLC). METHODS: The utilization information of medical resources in the NSCLC treatment regimes was collected from experts who were familiar with NSCLC treatment. The costs of 4 kinds of second-line drug treatment regimes were calculated using micro-simulation method. RESULTS: The costs of every cycle period(3 weeks)were 12 237.02 yuan for docetaxel regime, 12 102.82 yuan for gefitinib, 27 614.93 yuan for pemetrexed and 14 272.76 yuan for erlotinib. CONCLUSION: Gifitinib is not inferior to docetaxel in terms of pharmaeconomics for those with 6 months or longer period of anticipated progression-free survival.
